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Role of Circulating Fibroblast Growth Factor 21 Measurement in
Primary Prevention of Coronary Heart Disease Among Chinese
Patients With Type 2 Diabetes Mellitus
Chi Ho Lee, MD; Yu Cho Woo, MD; Wing Sun Chow, MD; Chloe Yu Yan Cheung, PhD; Carol Ho Yi Fong, MSc; Michele Mae Ann Yuen, MD;
Aimin Xu, PhD; Hung Fat Tse, MD, PhD; Karen Siu Ling Lam, MD
Background-—Fibroblast growth factor 21 (FGF21) has demonstrated beneﬁcial effects on lipid and carbohydrate metabolism. In
cross-sectional studies, an association of raised circulating FGF21 levels with coronary heart disease (CHD) was found in some but
not all studies. Here we investigated prospectively whether baseline serum FGF21 levels could predict incident CHD in subjects
with type 2 diabetes mellitus and no known cardiovascular diseases.
Methods and Results-—Baseline serum FGF21 levels were measured in 3528 Chinese subjects with type 2 diabetes mellitus
recruited from the Hong Kong West Diabetes Registry. The role of baseline serum FGF21 levels in predicting incident CHD over a
median follow-up of 3.8 years was analyzed using Cox regression analysis. Among 3528 recruited subjects without known
cardiovascular diseases, 147 (4.2%) developed CHD over a mean follow-up of 4 years. Baseline serum log-transformed FGF21
levels were signiﬁcantly higher in those who had incident CHD than those who did not (222.7 pg/mL [92.8–438.4] versus
151.1 pg/mL [75.6–274.6]; P<0.001). On multivariable Cox regression analysis, baseline serum FGF21 levels, using an optimal
cutoff of 206.22 pg/mL derived from our study, independently predicted incident CHD (hazard ratio, 1.55; 95% CI, 1.10–2.19;
P=0.013) and signiﬁcantly improved net reclassiﬁcation index and integrated discrimination improvement after adjustment for
conventional cardiovascular risk factors.
Conclusions-—We have demonstrated, for the ﬁrst time, that serum FGF21 level is an independent predictor of incident CHD and
might be usefully utilized as a biomarker for identifying type 2 diabetes mellitus subjects with raised CHD risk, for primary
prevention. ( J Am Heart Assoc. 2017;6:e005344. DOI: 10.1161/JAHA.116.005344.)
Key Words: adipokine • cardiovascular disease • coronary heart disease • primary prevention • type 2 diabetes mellitus
F ibroblast growth factor 21 (FGF21) is an emergingmetabolic hormone, secreted mainly from the liver, but
also from the adipose tissue, muscle, and pancreas.1
Treatment with FGF21 conferred beneﬁcial effects on body
weight, glucose, and lipid metabolism in animal studies,2 and
similar beneﬁts were demonstrated in humans treated with
FGF21 analogues.3,4 On the other hand, raised FGF21 levels
have been found in various cardiometabolic conditions in
clinical studies, suggesting a reactive change to FGF21
resistance or the underlying metabolic disturbances.1 In
population studies, we and others had previously shown that
high circulating FGF21 levels predicted the development of
type 2 diabetes mellitus (T2DM) and were associated with
carotid atherosclerosis independent of established cardiovas-
cular risk factors.5–9 Among subjects with T2DM, recently, we
also demonstrated that serum FGF21 levels predicted
nephropathy progression, in terms of decline in estimated
glomerular ﬁltration rate (eGFR), even in the stage of
normoalbuminuria and relatively preserved renal function,
highlighting its potential use as an early biomarker for diabetic
kidney disease, a devastating diabetic complication.10
Likewise, coronary heart disease (CHD) remains an impor-
tant macrovascular complication of T2DM,11 which, in turn,
has been suggested as a risk equivalent of CHD.12 Over the
years, the association of circulating FGF21 with CHD in T2DM
has not been clearly deﬁned. In cross-sectional studies,
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conﬂicting results were reported regarding circulating FGF21
levels in subjects with CHD, with an association of raised
FGF21 levels with CHD reported in some studies,13–15 but not
in others.16,17 The association of circulating FGF21 with CHD
in T2DM, especially among those without known cardiovas-
cular disease (CVD), remains to be deﬁned. Therefore, we
aimed to investigate longitudinally whether circulating FGF21
levels could be usefully utilized as a risk marker to predict the
development of CHD in subjects with T2DM and no known
CVD.
Subjects and Methods
Subjects
All subjects were recruited from the Hong Kong West
Diabetes Registry, which included patients who had T2DM
and were being regularly followed up at the medical specialist
clinics of the Hong Kong West Cluster since 2008. All Chinese
patients at enrollment to the registry had been invited to
participate in a prospective cohort study to identify the risk
factors, including serum and genetic biomarkers, predisposing
to the development of diabetic complications. Each visit
comprised of clinical assessments and laboratory investiga-
tions to determine the control of diabetes mellitus, its related
cardiovascular risk factors, and the presence of diabetic
complications.
In this study, subjects who were on ﬁbrates or had known
CVD at baseline were excluded. Consequently, a total of 3528
subjects were included in this study. The study protocol was
approved by the institutional review board of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster. All
recruited subjects gave written informed consent before any
study-related procedures.
Clinical and Biochemical Assessments
Subjects attended each visit after an overnight fasting of at
least 8 hours. At the baseline visit, demographic data,
including age, sex, occupation, smoking, alcohol consumption,
and physical activity, were obtained. Detailed family, medical,
and drug histories were ascertained using a standardized
questionnaire. Anthropometric parameters, including body
weight, height, body mass index, waist circumference, and
blood pressure, were measured. Fasting blood was drawn for
plasma glucose, lipids, and glycated hemoglobin. Serum
creatinine was measured and the eGFR was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
equation as described previously.18 Serum high-sensitivity
C-reactive protein was measured with a high-sensitivity,
particle-enhanced immunoturbidimetric assay (Roche Diag-
nostics, GmbH, Mannheim, Germany) and serum FGF21 was
measured with ELISA kits (Antibody and Immunoassay
Services, University of Hong Kong, Hong Kong, China).19,20
Deﬁnitions of Clinical Variables and Outcomes
Presence of dyslipidemia was deﬁned as fasting triglycerides
(TG) ≥1.69 mmol/L, high-density lipoprotein cholesterol
(HDL-C) <1.04 mmol/L in men and <1.29 mmol/L in women,
low-density lipoprotein cholesterol ≥3.4 mmol/L, or on lipid-
lowering agents. Hypertension was deﬁned as blood pressure
≥140/90 mm Hg or on antihypertensive medications. Inci-
dent CHD events, the primary outcome of interest in this
study, was deﬁned as the ﬁrst recorded diagnosis of
myocardial infarction and/or coronary revascularization, ver-
iﬁed from the Hospital Authority database or their private
practitioners as of March 31, 2016. Known CVD at baseline,
the exclusion criteria of the study, was deﬁned as any history
of myocardial infarction, stroke, transient ischemic attack,
heart failure, and coronary or other arterial revascularization.
Diagnoses of CHD events and other CVD were based on The
International Classiﬁcation of Diseases, Ninth Revision codes
(402, 404, 410–414, 425–447, and 518.4). In this study, the
medical diagnoses were adjudicated and reviewed by 2
physicians independently, and disagreements between them
were resolved by a third.
Statistical Analysis
All data were analyzed with IBM SPSS Statistics (version 23.0;
IBM Corp, Armonk, NY) and R software (Version 3.3.1;
Package survC1 and survIDINRI; R Foundation for Statistical
Computing, Vienna, Austria). Data that were not normally
distributed as determined using Kolmogorov–Smirnov test,
which included serum FGF21, TG, and high-sensitivity
C-reactive protein, were natural-logarithmically transformed
to obtain near normality before analysis. Values were reported
as meansSD, medians with interquartile range, or percent-
ages, as appropriate. Chi-square test and ANOVA test were
used for comparisons of categorical and continuous variables,
respectively. Pearson correlation and multiple linear regres-
sion analysis were used to evaluate the determinants of
serum FGF21 levels at baseline. To evaluate an optimal serum
FGF21 cutoff to predict incident CHD event, the point with the
maximum Youden index (J) was determined on the receiver-
operating characteristic operation curve with J=sensitiv-
ity+speciﬁcity1.21 Multivariable Cox regression analysis
was used to evaluate the association between baseline
circulating FGF21 levels and incident CHD events. The
variables included in Cox regression models were those that
were statistically signiﬁcant in the univariate analysis and with
minimal overlap in representation. Discrimination of serum
FGF21 levels in predicting incident CHD was analyzed using
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C-statistics.22 The incremental value of serum FGF21 levels
with reference to a baseline clinical model of conventional
cardiovascular risk factors in predicting incident CHD was
assessed by the integrated discrimination improvement and
the category-free net reclassiﬁcation index. CHD-free survival
curves were plotted by the Kaplan–Meier method and
subsequently compared by log-rank test. In all statistical
tests, 2-sided P<0.05 was considered signiﬁcant.
Results
A total of 3528 Chinese subjects with T2DM and no known
CVD were included in this prospective study. Table 1
summarizes their baseline characteristics. Over a median
follow-up of 3.8 (2.8–5.0) years, 147 subjects (4.2%) devel-
oped the ﬁrst CHD event, with a cumulative incidence of 10.1
per 1000 person-years. Subjects who had incident CHD
tended to be men, older, ever smoker, hypertensive with
higher systolic blood pressure, and longer duration of
diabetes mellitus with poorer glycemic control, as evident
by their higher fasting glucose and glycated hemoglobin
levels, and more of them had dyslipidemia and lower eGFR
than those who did not develop CHD. Whereas their serum
high-sensitivity C-reactive protein levels did not differ between
groups with and without incident CHD (1.34 mg/mL [0.60–
4.05] versus 1.24 mg/mL [0.50–2.99], respectively;
P=0.190), circulating log-transformed FGF21 levels were
signiﬁcantly higher in those who developed CHD compared
Table 1. Baseline Characteristics of the 3528 Subjects by Incident CHD
Baseline Variables Incident CHD No Incident CHD P Value
N 147 3381 
Men, % 66.7 51.1 <0.001*
Age, y 65.612.1 60.612.8 <0.001*
Ever smoker, % 34.7 28.7 0.023*
Duration of diabetes mellitus, years 14.99.23 11.68.67 <0.001*
Body mass index, kg/m2 26.14.19 26.04.65 0.940
Waist circumference, cm 0.438†
Men 90.911.9 90.412.3
Women 86.212.1 85.312.4
Systolic blood pressure, mmol/L 14321 13620 <0.001*
Diastolic blood pressure, mmol/L 7511 7510 0.587
Antihypertensive drug, % 88.4 78.0 0.003*
Hypertension, % 91.8 82.5 0.003*
Fasting glucose, mmol/L 8.572.79 7.832.51 <0.001*
Glycated hemoglobin, % (mmol/mol) 8.021.64 (64.217.9) 7.621.43 (59.815.7) 0.001*
PPAR-c‡, % 2.0 1.1 0.243
Estimated glomerular filtration rate
(CKD-EPI), mL/min per 1.73 m2
63.626.9 79.224.7 <0.001*
HDL-cholesterol, mmol/L 1.180.38 1.260.38 0.012*
LDL-cholesterol, mmol/L 2.730.98 2.520.80 0.002*
Triglyceride§, mmol/L 1.42 (1.03–2.24) 1.26 (0.90–1.79) 0.001*
Lipid-lowering drug, % 53.1 44.8 0.047*
Dyslipidemiak 85.7 78.4 0.034*
Highly sensitive C-reactive protein§, mg/mL 1.34 (0.60–4.05) 1.24 (0.50–2.99) 0.190
FGF21§, pg/mL 222.7 (92.8–438.4) 151.1 (75.6–274.6) <0.001*
Data are presented as meanSD or median (interquartile range); chi-square test and ANOVA test were used for comparisons of categorical and continuous variables, respectively. CHD
indicates coronary heart disease; CKD-EPI, chronic kidney disease epidemiology collaboration equation; FGF21, ﬁbroblast growth factor 21.
*P<0.05.
†
Sex-adjusted P value.
‡
PPAR-c, peroxisome proliferator-agonist receptor gamma.
§
Log-transformed before analysis.
k
Dyslipidemia was deﬁned as fasting triglycerides (TG) ≥1.69 mmol/L, high-density lipoprotein cholesterol (HDL-C) <1.04 mmol/L in men and <1.29 mmol/L in women, low-density
lipoprotein cholesterol (LDL-C) ≥3.4 mmol/L, or on lipid-lowering agents.
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with those who did not (222.7 pg/mL [92.8–438.4] versus
151.1 pg/mL [75.6–274.6], respectively; P<0.001).
In our study, baseline serum log-transformed FGF21 levels
correlated positively with body mass index (r=0.16), waist
circumference (r=0.19), systolic blood pressure (r=0.18),
serum TG (r=0.36), and high-sensitivity C-reactive protein
levels (r=0.20) and negatively with HDL-C (r=0.22) and
eGFR levels (r=0.27; all P<0.001). All remained signiﬁcant
independent determinants of baseline serum log-transformed
FGF21 levels on multiple linear regression analysis (Table S1).
On multivariable Cox regression analysis, using an optimal
serum FGF21 cutoff of 206.22 pg/mL obtained by Youden
index, circulating FGF21 level was conﬁrmed to be an
independent predictor of incident CHD in subjects with
T2DM without known CVD (hazard ratio [HR], 1.55; 95%
conﬁdence interval [95% CI], 1.10–2.19; P=0.013), together
with sex (HR, 2.04; 95% CI, 1.37–3.05; P<0.001), age (HR,
1.03; 95% CI, 1.01–1.05; P=0.003), baseline eGFR (HR, 0.986;
0.979–0.993), low-density lipoprotein cholesterol (HR, 1.39;
95% CI, 1.15–1.68; P=0.001), and lipid-lowering drugs (HR,
1.61; 95% CI, 1.13–2.29; P=0.008), in a model that also
included smoking status, duration of diabetes mellitus, use of
antihypertensive drugs, baseline glycated hemoglobin, sys-
tolic blood pressure, and HDL-C (Table 2). Importantly, its
association with incident CHD remained statistically signiﬁ-
cant irrespective of whether serum FGF21 level was
expressed as a continuous variable (log-transformed FGF21:
HR, 1.21; 95% CI, 1.02–1.43; P=0.026) or as a tertile cutoff of
224.22 pg/mL, comparing the highest with the lower 2 serum
FGF21 tertiles (HR, 1.47; 95% CI, 1.04–2.07; P=0.029). Figure
depicts the Kaplan–Meier analysis of incident CHD among
Table 2. Multivariable Cox Proportional Hazard Regression Model Showing the Association of Serum FGF21 Levels With Incident
CHD
Baseline Variables
Model 1 Model 2
Adjusted Hazard
Ratio (95% CI) P Value
Adjusted Hazard
Ratio (95% CI) P Value
Sex 2.17 (1.53–3.06) <0.001* 2.04 (1.37–3.05) <0.001*
Age, y 1.05 (1.03–1.06) <0.001* 1.03 (1.01–1.05) 0.003*
Ever smoker   1.07 (0.73–1.56) 0.727
Duration of diabetes mellitus, years   1.01 (0.99–1.03) 0.235
HbA1c, %   1.07 (0.96–1.19) 0.220
SBP, mm Hg   1.01 (1.00–1.02) 0.075
Antihypertensive drug, %   1.07 (0.62–1.86) 0.806
Estimated glomerular filtration
rate (CKD-EPI), mL/min per 1.73 m2
  0.986 (0.979–0.993) <0.001*
HDL-C, mmol/L   0.68 (0.40–1.13) 0.135
LDL-C, mmol/L   1.39 (1.15–1.68) 0.001*
Lipid-lowering drug, %   1.61 (1.13–2.29) 0.008*
FGF21 level ≥206.22 pg/mL† 1.98 (1.42–2.74) <0.001* 1.55 (1.10–2.19) 0.013*
CHD indicates coronary heart disease; CKD-EPI, chronic kidney disease epidemiology collaboration equation; FGF21, ﬁbroblast growth factor 21; HbA1c, glycated hemoblobin; HDL, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
*P<0.05.
†
Optimal serum FGF21 cutoff obtained by Youden Index.
Figure. Kaplan–Meier analysis of incident coronary heart disease
(CHD) among subjects stratiﬁed by tertiles of their serum ﬁbroblast
growth factor 21 (FGF21) levels at baseline.
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subjects stratiﬁed by tertiles of their serum FGF21 levels at
baseline. In view of the strong correlation between serum log-
transformed FGF21 and TG levels (Table S1), and that
increased serum TG together with low HDL-C levels have
been found to be highly associated with incident CHD in
subjects with T2DM,23 we further adjusted for the effect of TG
and found that serum FGF21 remained an independent
predictor of incident CHD (HR, 1.48; 95% CI, 1.04–2.11;
P=0.031)usinganoptimal serumFGF21cutoff of206.22 pg/mL
obtained by Youden index.
The discriminatory and reclassifying abilities of circulating
FGF21 levels are shown in Table 3. The addition of serum
FGF21 level, whether as a log-transformed variable, optimal or
tertile cutoff, to a baseline clinical model consisting of
conventional cardiovascular risk factors, including sex, age,
smoking status, duration of diabetes mellitus, glycated
hemoglobin, systolic blood pressure, use of antihypertensive
drugs, eGFR, HDL-C, low-density lipoprotein cholesterol, and
use of lipid-lowering drugs, resulted in comparable C-statistics
and therefore did not improve discrimination with regard to
the prediction of incident CHD. However, in contrast, in terms
of reclassiﬁcation, the addition of serum FGF21 level,
irrespective of using it as a log-transformed variable, optimal
or tertile cut-ff, all provided signiﬁcant improvements in
integrated discrimination improvement to the baseline clinical
model (integrated discrimination improvement +0.004,
+0004, and +0.003; P=0.018, 0.020, and 0.026, respec-
tively). Furthermore, both optimal and tertile serum FGF21
cutoffs resulted in a modest, yet signiﬁcant, increase in
category-free net reclassiﬁcation index in predicting incident
CHD (net reclassiﬁcation index +0.179 and +0.170; P=0.032
and 0.048, respectively). Taken together, among Chinese
subjects with T2DM and no known CVD, the addition of
circulating FGF21 levels, preferably using an optimal cutoff of
206.22 pg/mL, to conventional cardiovascular risk factors,
improved reclassiﬁcation and retained considerable discrim-
ination in CHD prediction.
Discussions
In this prospective study, we demonstrated, for the ﬁrst time,
that, circulating FGF21 levels independently predicted the
development of CHD in subjects with T2DM and no known
CVD. Our ﬁndings have expanded the current understanding
on the relationship between serum FGF21 and CHD. Several
cross-sectional studies had shown that serum FGF21 levels
were signiﬁcantly higher in subjects with CHD than those in
controls.13,14 In a study involving 100 Chinese subjects, with
38% of them having T2DM, serum FGF21 levels were
independently associated with the presence of acute
myocardial infarction and were signiﬁcantly higher in those
who developed reinfarction within 30 days.15 However,
conﬂicting results were also reported from a few studies,
which showed a lack of signiﬁcant association after adjusting
for body mass index and glycemic status.16,17 Given that
circulating FGF21 levels were higher in T2DM,6,9 and most
cross-sectional studies consisted of relatively small sample
size and therefore a limited number of subjects with T2DM,
the association of serum FGF21 with CHD in T2DM could
only be, at most, speculative. Nonetheless, to our knowledge,
2 prospective studies were available that looked into the
relationship between circulating FGF21 levels and CVD in
Table 3. Discrimination and Reclassiﬁcation Performance of the Addition of Circulating FGF21 Levels in Predicting Incident CHD,
Based on C-Statistics, NRI, and IDI
Model
Addition of Circulating FGF21
Levels to the Baseline
Clinical Model C-Statistics (95% CI) P Value Category Free NRI (95% CI) P Value IDI (95% CI) P Value
Baseline
clinical
model*
0.7449 (0.6830–0.8067)    
FGF21 levels† 0.7458 (0.6830–0.8067) 0.442 0.051 (0.068 to 0.158) 0.342 0.004 (0.0001–0.017) 0.018‡
FGF21
≥206.22 pg/mL§
0.7467 (0.6817–0.8117) 0.343 0.179 (0.039–0.273) 0.032‡ 0.004 (0.0001–0.013) 0.020‡
FGF21
≥224.22 pg/mLk
0.7457 (0.6813–0.8102) 0.389 0.170 (0.003–0.263) 0.048‡ 0.003 (0.0001–0.012) 0.026‡
CHD indicates coronary heart disease; FGF21, ﬁbroblast growth factor 21; HDL, high-density lipoprotein cholesterol; IDI, integrated discrimination improvement; LDL-C, low-density
lipoprotein cholesterol; NRI, net reclassiﬁcation index.
*Baseline clinical model included sex, age, smoking status, duration of diabetes mellitus, glycated hemoglobin, systolic blood pressure, use of antihypertensive drugs, estimated glomerular
ﬁltration rate, HDL-C, LDL-C, and use of lipid-lowering drugs.
†
Circulating FGF21 levels as a log-transformed variable.
‡
P<0.05.
§
Optimal serum FGF21 cutoff obtained by Youden Index.
k
Serum FGF21 tertile cutoff obtained by comparing the highest with the lower 2 serum FGF21 tertiles as referent.
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subjects with T2DM. As part of the FIELD (Fenoﬁbrate
Intervention and Event Lowering in Diabetes) study, plasma
FGF21 levels were measured at baseline in 9697 subjects
with T2DM. Circulating FGF21 levels were found to be
predictive of the primary outcome of total CVD over a
median follow-up of 5 years. However, analyses of secondary
outcomes showed that the associations were positive for
stroke, coronary, and carotid revascularization, but not CHD
events, after adjusting for established CVD risk factors.20
A small study on 87 T2DM subjects from Poland also
reported a predictive role of serum FGF21 levels with
incident cardiovascular morbidity and mortality over
2 years,24 but no information on the prediction of incident
CHD was provided. Notably, both studies consisted of a
signiﬁcant number of subjects with known CVD at baseline,
22% in FIELD and 64.4% in the Polish study, and around half
of the subjects in the FIELD study were on fenoﬁbrate, a
peroxisome proliferator-agonist receptor alpha agonist that
enhances FGF21 expression.1 Thus, our study was the ﬁrst
one to demonstrate a prospective, independent relationship
between raised serum FGF21 levels with incident CHD. Our
ﬁndings would suggest its potential application as a
biomarker for risk stratiﬁcation in primary prevention of
CHD among subjects with T2DM.
Our ﬁndings of elevated circulating FGF21 levels in
subjects who developed CHD could be explained, at least in
part, by FGF21 resistance that had also been reported in other
cardiometabolic conditions.6,8,10,20,25 The increase in circu-
lating FGF21 levels might also reﬂect a protective compen-
satory response to insulin resistance or hyperinsulinemia,
hyperlipidemia, and the increase in systemic inﬂammation in
patients with atherosclerotic diseases.26,27 In fact, multiple
beneﬁcial effects of FGF21 in the context of CHD had been
demonstrated in preclinical studies. Mice with combined
apolipoprotein E and FGF21 deﬁciency had worsened hyper-
lipidemia, increased expressions of both local and systemic
proinﬂammatory chemokines and cytokines, with resultant
acceleration of aortic plaque formation,28 compared with mice
with apolipoprotein E deﬁciency only. Although these
antiatherosclerotic properties of FGF21 could be explained
by adiponectin, which had been shown to mediate the effects
of FGF21 on glucose homeostasis and insulin sensitivity in
mice,29 FGF21 could also ameliorate atherosclerosis inde-
pendent of adiponectin, through suppression of cholesterol
biosynthesis by directly inhibiting sterol regulatory element-
binding protein-2.28 In another study using FGF21 knockout
mice and cultured rat neonatal cardiomyocytes, FGF21
deﬁciency enhanced isoproterenol induced cardiac hypertro-
phy, increased cardiac expressions of proinﬂammatory genes,
as well as markers of cardiac hypertrophy and ﬁbrosis.
Importantly, FGF21 treatment reversed the above adverse
effects both in vitro and in vivo.30 Moreover, in vitro studies
using THP1 macrophage derived foam cells also demon-
strated that FGF21 could decrease oxidized low-density
lipoprotein cholesterol–related foam cell formation and
apoptosis.31 Taken together, the elevation of circulating
FGF21 levels observed in our study might also reﬂect a
protective bodily response to myocardial ischemia or injury
during CHD development, similar to that observed in
acetaminophen-induced hepatotoxicity we described
previously.32
Not until recently, FGF21 is regarded as a major
hepatokine, and also an adipokine and myokine, though to a
lesser extent. In response to myocardial ischemia in mice,
both hepatic and adipocyte-derived FGF21 expression and
secretion were shown to be upregulated, highlighting a
cardioprotective response of FGF21 in an endocrine man-
ner.33 Recently, both cardiac FGF21 expression and secretion
were also found to be increased signiﬁcantly with isopro-
terenol treatment in mice and phenylephrine treatment in
neonatal cardiomyocytes, respectively.30 Furthermore, car-
diac ischemia was able to induce signiﬁcant increases in
cardiac FGF21 mRNA, protein expression, and secretion
ex vivo in a rat heart Langendorff model, suggesting possible
autocrine or paracrine cardioprotective effects during myocar-
dial ischemia.34 However, the extent of contribution from this
cardiac production of FGF21 to the elevated circulating FGF21
levels observed in our subjects with T2DM and incident CHD
remains uncertain.
In the current study, not only have we identiﬁed a
predictive role of serum FGF21 level on incident CHD in
subjects with T2DM and no known CVD, but we also
demonstrated that the addition of serum FGF21 above
206.22 pg/mL, an optimal cutoff derived from our cohort,
to a baseline clinical model consisting of conventional
cardiovascular risk factors, resulted in a modest, yet signif-
icant, improvement in both category-free NRI and IDI. Our
ﬁndings have provided useful information from a clinician’s
perspective. Current clinical guidelines do not advocate
routine screening for CHD in asymptomatic patients with
T2DM, given that risk factor-based screening strategy is not
sensitive and some noninvasive coronary assessment carries
radiation risks.35 Therefore, in the setting of primary preven-
tion of CHD in T2DM, our ﬁndings would suggest the need to
validate the potential use of FGF21, a serum biomarker that
can be readily assessed using commercially available assay,
for coronary risk stratiﬁcation.
Our study, however, is limited by the relatively low event
rate and short duration of follow-up. Furthermore, attributed
to registry design and recommendations from current clinical
guidelines,35 a screening test for myocardial ischemia was not
routinely performed in our asymptomatic subjects with T2DM.
Nonetheless, although silent myocardial ischemia is not
uncommon in T2DM, there have also been data showing that
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it might reverse over time,36 and adverse cardiac outcomes
were similar in those who had silent myocardial ischemia
compared with those who did not.37 Notwithstanding these
limitations, we have provided the ﬁrst demonstration that
elevated circulating FGF21 level was an independent predictor
of incident CHD in patients with T2DM and no known CVD. In
recent years, despite the more-liberal use of statins in T2DM,
in particular, moderate-to-high intensity statins as driven by
the latest guidelines,35 substantial health burden from CHD
still exists. We previously showed that circulating FGF21 had
the potential to become a novel marker for nephropathy
development in early stages of diabetic kidney disease; our
current ﬁndings further proposed that it might also be usefully
utilized in risk stratiﬁcation in the setting of primary CHD
prevention among subjects with T2DM.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
 
Table S1. Multiple linear regression analysis showing the determinants of serum log-transformed 
fibroblast growth factor 21 levels at baseline 
 
Variable at baseline Standardized beta p-value 
TG* 0.300 <0.001 
eGFR (EPI) 0.192 <0.001 
hsCRP* 0.088 <0.001 
Age 0.067 0.001 
SBP 0.057 0.001 
BMI# 0.053 0.002 
HDL-C -0.044 0.012 
 
FGF21 indicates fibroblast growth factor 21; TG, triglyceride; eGFR, estimated glomerular filtration rate; 
hsCRP, high sensitivity C reactive protein; SBP, systolic blood pressure; BMI, body mass index; HDL-C, 
high density lipoprotein cholesterol. 
*Natural log-transformed before analysis 
#Result remained the same when BMI replaced by waist circumference 
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